Risk of HBV reactivation in patients with B-cell lymphomas receiving obinutuzumab or rituximab immunochemotherapy

Risk of hepatitis B virus (HBV) reactivation was assessed in B-cell non-Hodgkin lymphoma (NHL) patients with resolved HBV infection (hepatitis B surface antigen negative, hepatitis B core antibody positive) who received obinutuzumab- or rituximab-containing immunochemotherapy in the phase 3 GOYA and...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Blood
Main Authors: Kusumoto, Shigeru, Arcaini, Luca, Hong, Xiaonan, Jin, Jie, Kim, Won Seog, Kwong, Yok Lam, Peters, Marion G., Tanaka, Yasuhito, Zelenetz, Andrew D., Kuriki, Hiroshi, Fingerle-Rowson, Günter, Nielsen, Tina, Ueda, Eisuke, Piper-Lepoutre, Hanna, Sellam, Gila, Tobinai, Kensei
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Hematology 2019
Assuntos:
Clinical Trials and Observations
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6337873/
https://ncbi.nlm.nih.gov/pubmed/30341058
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2018-04-848044
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados